一種常見(jiàn)腸道病毒能夠清除自身移植干細(xì)胞化療之后的癌癥細(xì)胞。

一種新型藥物包含人類呼吸道腸道孤兒病毒(reovirus)，叫做Reolysin，被設(shè)計(jì)用于清除自身干細(xì)胞移植物中的癌癥細(xì)胞，這些癌細(xì)胞會(huì)在高劑量化療之后重新出現(xiàn)。當(dāng)進(jìn)入血液之中的時(shí)候，能夠在其中復(fù)制，并最終殺死它們。這種reovirus病毒在癌細(xì)胞內(nèi)復(fù)制，從而激活Ras信號(hào)途徑，這是一種常見(jiàn)的突變，在大約三分之二的人類腫瘤中存在。Oncolytics生物科技公司(Calgary, Canada)研制開(kāi)發(fā)了Reolysin。

Virus Purges Cancer Cells in Stem Cell Transplants
 
A common enteric virus may be able to eliminate cancer cells from autologous stem cell transplants following chemotherapy.

A new proprietary formulation of the human respiratory enteric orphan virus (reovirus) called Reolysin is designed to purge cancer cells from autologous stem cell transplants that are reintroduced to the body following high-dose chemotherapy. When introduced into the blood, the reovirus enters cancer cells,replicates within them, and ultimately kills them. The reovirus works by replicating within cancer cells that have an activated Ras pathway, a common mutation that is shared by approximately two-thirds of all human cancers. Reolysin was developed by Oncolytics Biotech (Calgary, Canada).